Article
Rheumatology
Renske C. F. Hebing, Marry Lin, Maja Bulatovic Calasan, Ittai B. Muller, Sohaila Mahmoud, Sandra Heil, Eduard A. Struys, Bart J. F. van den Bemt, Jos W. R. Twisk, Willem Lems, Michael T. Nurmohamed, Gerrit Jansen, Robert de Jonge
Summary: This study investigates the pharmacokinetics of methotrexate polyglutamate (MTX-PG) accumulation in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs) in patients with early rheumatoid arthritis (RA) after oral and subcutaneous MTX treatment. The results show that there are disparate pharmacokinetic profiles between PBMCs and RBCs, with higher accumulation of MTX-PG in PBMCs. The distribution profile of MTX-PG in PBMCs remains constant over 6 months, while in RBCs, the main PG-moiety changes from MTX-PG(1) to MTX-PG(3).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Medicine, General & Internal
Eric Senbel, Sonia Trope, Helene Herman-Demars, Elena Zinovieva, Agnes Courbeyrette, Pierre Clerson, Yann Fardini, Rene-Marc Flipo
Summary: The APRIM study aimed to investigate the impact of switching from oral to subcutaneous methotrexate on treatment adherence, disease control, and quality of life in rheumatoid arthritis patients. Results demonstrated that the transition to subcutaneous route improved adherence, disease activity control, and quality of life for patients.
PATIENT PREFERENCE AND ADHERENCE
(2021)
Article
Rheumatology
Janne Heuvelmans, Nathan den Broeder, Geke A. H. van den Elsen, Alfons A. den Broeder, Bart J. F. van den Bemt
Summary: This study aimed to compare the effectiveness and tolerability of oral MTX and s.c. MTX in RA patients. The results showed that oral MTX was non-inferior to s.c. MTX in terms of disease activity control, with a slightly lower dose and better tolerability.
Article
Chemistry, Multidisciplinary
Parvathy Suresh, Mounir M. Salem-Bekhit, Hafsa Palathum Veedu, Sultan Alshehri, Sreeja Chandrasekhar Nair, Sarah Bukhari, Vidya Viswanad, Ehab Taha, Ram Kumar Sahu, Mohammed M. Ghoneim, Ibrahim Elbagory
Summary: A novel formulation of methotrexate-loaded nanoemulsion was developed to deliver methotrexate into the system via the lymph for the treatment of rheumatoid arthritis. The optimized nanoemulsion showed excellent physicochemical properties, significant anti-arthritic activity, and stability when stored at a low temperature.
Article
Multidisciplinary Sciences
Helen R. Gosselt, Costanza L. Vallerga, Pooja R. Mandaviya, Erik Lubberts, Johanna M. W. Hazes, Robert de Jonge, Sandra G. Heil
Summary: The study did not identify genome-wide significant differences as biomarkers for Methotrexate (MTX) therapy response, necessitating meta-analyses.
Article
Rheumatology
Ulf Lindstrom, Daniela di Giuseppe, Sofia Exarchou, Gerd-Marie Alenius, Tor Olofsson, Eva Klingberg, Lennart Jacobsson, Johan Askling, Johan K. Wallman
Summary: This study aimed to compare the treatment outcomes of patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) using methotrexate (MTX) monotherapy. The results showed that PsA patients were less likely to continue the use of MTX compared to RA patients, and the effectiveness of MTX was also lower in PsA.
Review
Pharmacology & Pharmacy
Gurleen Kour, Syed Assim Haq, Bijender Kumar Bajaj, Prem N. Gupta, Zabeer Ahmed
Summary: Phytochemicals have long been known for their therapeutic potential in autoimmune disorders such as rheumatoid arthritis, but their combination with DMARDs can increase the efficacy of treatment while reducing toxic side effects. Studies have shown promising results in experimental and clinical settings when combining phytochemicals with DMARDs, highlighting the importance of this approach in future RA therapy.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Medicine, Research & Experimental
Marion Geoffroy, Claire Gozalo, Celine Konecki, Loic Pauvele, Ambre Hittinger, Noemie Pastorel, Catherine Feliu, Jean Hugues Salmon, Zoubir Djerada
Summary: This study used population pharmacokinetic modeling to describe the kinetics of urinary methotrexate in treated patients and evaluate its ability to assess methotrexate adherence. The results showed that urinary methotrexate was independently associated with methotrexate administration with high sensitivity and specificity. By developing a pharmacokinetic model and conducting simulations, the proportion of true positive samples can be predicted.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Rheumatology
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Summary: This study evaluated the safety and efficacy of ABX464 in patients with moderate-to-severe active rheumatoid arthritis. The results showed that ABX464 at a 50 mg dose was safe, well tolerated, and showed promising efficacy. The 100 mg dose had a high dropout rate due to gastrointestinal adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Rheumatology
Yoshiya Tanaka
Summary: Methotrexate (MTX), a conventional synthetic disease-modifying antirheumatic drug, is used to treat rheumatoid arthritis. Recent studies suggest that subcutaneous MTX can reduce gastrointestinal side effects and improve drug efficacy.
MODERN RHEUMATOLOGY
(2023)
Article
Nanoscience & Nanotechnology
Jiayao Lyu, Lujun Wang, Xiaosheng Bai, Xingjie Du, Jun Wei, Jianxin Wang, Yan Lin, Zhenyu Chen, Zhongbing Liu, Jianming Wu, Zhirong Zhong
Summary: This study successfully loaded methotrexate (MTX) into nanoparticles of human serum albumin modified with mannose for targeted drug delivery to neutrophils, reducing toxicity and showing significant anti-inflammatory, antiangiogenic, and anti-arthritic effects in experimental models. The nanoparticles prolonged the in vivo circulation of MTX and accumulated mainly in arthritic joints, indicating their potential as a useful drug delivery system for rheumatoid arthritis.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Medicine, General & Internal
Alberto Floris, Daniela Perra, Ignazio Cangemi, Mattia Congia, Elisabetta Chessa, Maria Maddalena Angioni, Arduino Aleksander Mangoni, Gian Luca Erre, Alessandro Mathieu, Matteo Piga, Alberto Cauli
Summary: The study identified current smoking as a predictor of inadequate response to methotrexate in rheumatoid arthritis patients. Other independent predictors of treatment response were also found, which may assist in personalized monitoring of RA patients. Further research is needed to investigate whether smoking cessation strategies enhance the therapeutic response to methotrexate.
Article
Rheumatology
David Stahl, Carola Tho Pesch, Carolin Bruck, Ruth L. Esser, Jan Thiele, Veronica Di Cristanziano, David M. Kofler
Summary: Concurrent use of methotrexate may reduce the humoral immune response to COVID-19 vaccination in patients with rheumatoid arthritis (RA), particularly in elderly patients. Younger patients are less affected by methotrexate in terms of immune response.
Article
Chemistry, Multidisciplinary
Alexandre Bordat, Tanguy Boissenot, Nada Ibrahim, Marianne Ferrere, Manon Leveque, Lea Potiron, Stephanie Denis, Sebastien Garcia-Argote, Olivia Carvalho, Jerome Abadie, Catherine Cailleau, Gregory Pieters, Nicolas Tsapis, Julien Nicolas
Summary: Chemotherapy is commonly administered via the intravenous route, but has limitations. Researchers have developed a new method for subcutaneous administration of anticancer drugs through the design of hydrophilic polymer prodrugs, which successfully avoids local toxicity and outperforms commercial formulations.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2022)
Article
Engineering, Biomedical
Jia Tian, Tao Chen, Baoxuan Huang, Yang Liu, Chao Wang, Zepeng Cui, Hao Xu, Qiang Li, Weian Zhang, Qianqian Liang
Summary: In this study, a inflammation-specific environment activated methotrexate-encapsulated nanomedicine (MTX@NPs) was developed for the treatment of rheumatoid arthritis (RA). It effectively accumulated in inflamed joints and released methotrexate in the specific RA microenvironment. MTX@NPs demonstrated a high therapeutic efficacy for RA with minimal systemic toxicity by suppressing inflammation response and improving lymphatic functions.
ACTA BIOMATERIALIA
(2023)